2026-01-24 - Analysis Report
**Report for Johnson & Johnson (JNJ)**

**Overview**
Johnson & Johnson is a multinational healthcare company that develops medical devices, pharmaceuticals, and consumer goods.

**Return Rate Comparison**
- Ticker: JNJ
- Cumulative Return: 77.70%
- Cumulative Return (VOO): 126.41%
- Divergence: -48.70 (Relative Divergence: 40.60%)

The cumulative return of JNJ is lower than the S&P 500 (VOO) by 48.71 percentage points.

**Performance Analysis**
| Year | CAGR | MDD | Alpha | Beta | Cap (B) |
|------|------|-----|-------|------|----------|
| 2016-2018 | 6.0% | 16.9% | -6.0% | 0.7 | 310.9B |
| 2017-2019 | 21.0% | 16.9% | -5.0% | 0.7 | 351.4B |
| 2018-2020 | 13.0% | 26.1% | -12.0% | 0.7 | 379.2B |
| 2019-2021 | 27.0% | 26.1% | -38.0% | 0.6 | 412.2B |
| 2020-2022 | 17.0% | 26.1% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -10.0% | 14.3% | -30.0% | 0.3 | 377.6B |
| 2022-2024 | -23.0% | 14.3% | -53.0% | 0.2 | 348.4B |
| 2023-2025 | 37.0% | 14.3% | -38.0% | 0.1 | 498.6B |

JNJ's CAGR and MDD show volatility over the years. The Alpha and Beta values are relatively consistent, with some fluctuations.

**Recent Stock Price Fluctuations**
- Close: $220.14
- Last-Market: {'price': 220.14, 'previousClose': 218.49, 'change': 0.76}
- 5-day SMA: $218.70
- 20-day SMA: $211.30
- 60-day SMA: $203.76

The stock price has shown a slight increase over the last day, with the 5-day SMA lower than the current price.

**RSI, PPO, and Delta Analysis**
- Market Risk Indicator (MRI): 0.70
- RSI: 72.69
- PPO: 0.38
- Relative Divergence: 40.60%
- Recent relative divergence change: 1.40 (+)
- 7-day Rank change: 86 (+)
- 7-day Dynamic Expected Return change: -25.70 (-)

The RSI and PPO values indicate a moderate level of buying activity. The Relative Divergence is higher than usual.

**Expected Return**
- Expected Return (%): -64.10%
- Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point: -64.10%

**Recent News & Significant Events**

1. 2026-01-22: "How Two Rivals Undercut J&J's Beat And Big Guidance" (Investor's Business Daily)
2. 2026-01-21: "Netflix, Kraft Heinz and Johnson & Johnson fall premarket; United Airlines rises" (Investing.com)
3. 2026-01-21: "Johnson & Johnson forecasts 2026 profit above Wall Street estimates" (CNBC)
4. 2026-01-23: "Johnson & Johnson Quietly Triggers a Trend Following Buy Signal" (MarketBeat)
5. 2026-01-23: "How Johnson & Johnson’s 2025 Beat and 2026 Sales Guidance Could Shape JNJ Investors’ Outlook" (Yahoo Finance New Zealand)
6. 2026-01-21: "Johnson & Johnson (NYSE:JNJ) Beats Q4 Estimates but Stock Dips on 2026 Guidance" (Chartmill)

These news headlines indicate a mixed reaction to Johnson & Johnson's recent performance and guidance.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.21 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 224.09 / 265.00 / 155.00

Most analysts recommend buying JNJ, with an average target price of 224.09.

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

JNJ's EPS and revenue have shown some fluctuations over the past few quarters.

**Financial Information: Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |

JNJ's revenue and profit margin have shown some fluctuations over the past few quarters.

**Comprehensive Analysis (Summary of Previous Items)**
Johnson & Johnson's performance has been mixed, with a lower cumulative return compared to the S&P 500. The RSI and PPO values indicate moderate buying activity, while the Relative Divergence is higher than usual. The expected return is negative, indicating a potential decline in the stock price. News headlines have shown a mixed reaction to the company's recent performance and guidance. Analyst opinions recommend buying the stock, with an average target price of 224.09.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.